Maria Ervandian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Ervandian has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Lisa Sengeløv
C Department of Oncology , Herlev Hospital , Herlev , Denmark
2 shared publicationsMichael Borre
A Department of Urology , Aarhus University Hospital , Aarhus N , Denmark
2 shared publications- Morten Høyer
Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
2 shared publications Peter Meidahl Petersen
F Department of Oncology , Rigshospitalet , København Ø , Denmark
2 shared publications- Steinbjørn Hansen
Department of Oncology, Odense University Hospital, Odense, Denmark
2 shared publications Joen Sveistrup
F Department of Oncology , Rigshospitalet , København Ø , Denmark
1 shared publication
Latest Publications
- 27 July 2017
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 51 (6) , 457-463
Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer
Objective: There is a paucity of knowledge of long-term urinary morbidity in patients treated for prostate cancer (PCa) with radical prostatectomy (RP) and salvage radiotherapy (SRT). Improved long-term survival calls for heightened awareness of late effects from radiotherapy after RP. The purpose of this study was to assess late urinary morbidity and its potential impact on quality of life (QoL) in patients treated with RP plus SRT compared with patients treated with RP alone. Materials and methods: Long-term morbidity and QoL were evaluated using a cross-sectional design with validated questionnaires in urinary morbidity [Danish Prostatic Symptom Score (DAN-PSS)] and QoL [European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)]. Included were a total of 227 patients treated with SRT and 192 treated with RP in the periods 2006–2010 and 2005–2007, respectively. Results: Weak stream, straining, frequency and nocturia were significantly more prevalent in patients treated with RP + SRT than in patients treated with RP alone. Patients treated with RP + SRT generally suffered from more severe urinary symptoms. The QoL scores of the two treatment groups were not statistically significantly different, but a high level of urinary morbidity was significantly related to decreased QoL (p = 0.000). Conclusions: Patients treated with SRT have a higher rate of urinary morbidity than do patients treated with RP alone. Severe urinary morbidity was significantly related to decreased QoL, but did not differ between the two treatment groups.
- 27 July 2017
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 51 (6) , 457-463
Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer
Objective: There is a paucity of knowledge of long-term urinary morbidity in patients treated for prostate cancer (PCa) with radical prostatectomy (RP) and salvage radiotherapy (SRT). Improved long-term survival calls for heightened awareness of late effects from radiotherapy after RP. The purpose of this study was to assess late urinary morbidity and its potential impact on quality of life (QoL) in patients treated with RP plus SRT compared with patients treated with RP alone. Materials and methods: Long-term morbidity and QoL were evaluated using a cross-sectional design with validated questionnaires in urinary morbidity [Danish Prostatic Symptom Score (DAN-PSS)] and QoL [European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)]. Included were a total of 227 patients treated with SRT and 192 treated with RP in the periods 2006–2010 and 2005–2007, respectively. Results: Weak stream, straining, frequency and nocturia were significantly more prevalent in patients treated with RP + SRT than in patients treated with RP alone. Patients treated with RP + SRT generally suffered from more severe urinary symptoms. The QoL scores of the two treatment groups were not statistically significantly different, but a high level of urinary morbidity was significantly related to decreased QoL (p = 0.000). Conclusions: Patients treated with SRT have a higher rate of urinary morbidity than do patients treated with RP alone. Severe urinary morbidity was significantly related to decreased QoL, but did not differ between the two treatment groups.
- Open Access
- 23 September 2015
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 55 (5) , 598-603
Salvage radiation therapy following radical prostatectomy. A national Danish study
Background: The purpose of this observational cohort study was to evaluate the outcome and prognostic factors following salvage radiotherapy (SRT) in a consecutive national cohort. Material and methods: Between 2006 and 2010, 259 patients received SRT in Denmark. Patient- and cancer-related characteristics were retrospectively retrieved from patient charts. The primary end point was biochemical progression-free survival (b-PFS). Results: At the end of follow-up, 51% of the patients displayed a prostate-specific antigen (PSA) level 0.2 ng/ml benefitted from additional ADT.
- 23 September 2015
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 55 (5) , 598-603
Open AccessSalvage radiation therapy following radical prostatectomy. A national Danish study
Background: The purpose of this observational cohort study was to evaluate the outcome and prognostic factors following salvage radiotherapy (SRT) in a consecutive national cohort. Material and methods: Between 2006 and 2010, 259 patients received SRT in Denmark. Patient- and cancer-related characteristics were retrospectively retrieved from patient charts. The primary end point was biochemical progression-free survival (b-PFS). Results: At the end of follow-up, 51% of the patients displayed a prostate-specific antigen (PSA) level 0.2 ng/ml benefitted from additional ADT.